LIFE SCIENCE VENTURES

SHAPING NEW LIFE SCIENCE OPPORTUNITIES.

Ventac Partner’s international team builds new life science companies worldwide. We have a proven track record in founding and growing innovative companies in partnership with our stakeholders and investors. We develop and implement successful global business strategies for our companies that are designed to attract investment, develop the technology and provide attractive exits. Meet our international team here.

OUR APPROACH TO NEW VENTURES

Once Ventac Partners identifies a high-value opportunity with the right fundamentals, we work with our clients to create a new business. We support the new venture by providing a seasoned management team that immediately enhances value and investor confidence. And we continue to help the company grow and remain competitive through strategic advice and hands-on assistance building the business plan, negotiating and executing licensing deals and keeping investor relations, M & A and patent portfolio development at best international practice.

Individual partners or the partner team are the co-founder(s) of the following companies:

Ventac Center for Drug Development

The Ventac Center for Drug Development (VCDD) is a Hong Kong based company focusing on transforming breakthrough scientific discoveries into tangible products for the benefit of patients and society. VCDD takes active responsibility for developing promising early stage discovery programs according to pharmaceutical drug development processes and standards. VCDD’s mission is to assist top-tier research institutions in Hong Kong and China in entering commercial partnerships with the pharmaceutical industry and ensuring that important research findings are converted to real-life pharmaceutical products.

VCDD uses the international Ventac Partners team to bridge the gap between promising, early stage research programs and formal product development before licensing the technologies to the pharmaceutical industry.

CONTACT: Peter Damsbo, Partner, MD at pdamsbo@ventac-partners.com. See OUR TEAM.

APIM Therapeutics AS - www.apimtherapeutics.com

Incorporated in 2009, APIM Therapeutics AS is a spin out of the Norwegian University of Science and Technology (NTNU), Department of Cancer Research and Molecular Medicine in Trondheim, Norway. Based on a novel therapeutic approach targeting DNA repair and cell cycle control, APIM Therapeutics AS develops novel co-drugs with the potential to improve safety and efficacy of many current chemotherapeutic treatments for the benefit of cancer patients.

Regenesance BV - www.regenesance.com

Regenesance is a 2009 spin-out of the Academic Medical Center (AMC) in Amsterdam, the Netherlands. Based on a novel therapeutic intervention point, the Company is developing new compounds that may reduce nervous system injury in patients. One compound (RGS1102) significantly enhances nerve function in an animal model of acute nerve damage. Preliminary results in animals with another compound (RGS2064) suggest it may reduce nerve damage after traumatic brain injury (TBI).

Avexxin AS - www.avexxin.com

Avexxin is a 2005 spin-out based on research conducted at the Norwegian University of Science and Technology and Oslo University. Avexxin is a pharmaceutical company focusing on development of novel small molecule therapeutics for patients with chronic inflammatory conditions. Avexxin's lead compound (AVX001) is targeted at psoriasis and other chronic dermatological disorders. Other development programs of the company are directed at the development of compounds for rheumatoid arthritis and glomerulonephritis.

Exiqon A/S – www.exiqon.com

Listed in 2007 on the Nasdac OMX stock exchange in Copenhagen, Exiqon operates in two business areas: life sciences and cancer diagnostics. Exiqon is the home of LNA™ based tools for small RNA research and in diagnostics Exiqon is a market leader in the field of in vitro treatment selection testing for cancer. Exiqon performs innovative genomic research aimed at rapidly identifying new cancer diagnostics to improve the outcome of cancer patients.

Santaris Pharma A/S – www.santaris.com

Santaris Pharma A/S, is an international clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The Company's proprietary Locked Nucleic Acid (LNA) Drug Platform, in combination with its highly specialized and targeted drug development capabilities, offers potential partners pre-screened drug candidates for commercial consideration across a multitude of disease states. Santaris Pharma A/S research and development activities focus on infectious diseases and metabolic disorders while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, rare genetic disorders and inflammatory diseases. Santaris Pharma A/S, founded in 2003, is privately-held and headquartered in Denmark with operations in the US . As part of its broad patent estate, the Company holds exclusive worldwide rights to all therapeutic uses of LNAs. The Company has strategic partnerships with Enzon Pharmaceuticals, GlaxoSmithKline, Wyeth Pharmaceuticals (now part of Pfizer) and Shire plc.

Back to top

Martin Austin
Partner
Ventac Partners are experts in creating spin-outs from pharma, large biotech and medtech and universities. Our portfolio expands by two to three companies per year. We take the spin-outs to where the conditions for growth and financing are most optimnal. Over the years, our clients also seek our active engagement in the role of chairman or board member in these companies.

Konstantinos Alevizopoulos
Partner, PhD, CEO of
APIM Therapeutics AS
Ventac Partners were heavily engaged in transforming the ground breaking technology behind APIM Therapeutics into a promising business opportunity. We provided a full range of pre-clinical advise services, recruited quality and cost efficient CRO services and collaborated with the inventors, the Norwegian University of Science and Technology and the university’s technology transfer office in recruiting venture capital injected in the company in three seed financing rounds. Currently, Ventac Partners provide the CEO and continue to strategically advise the company’s board and shareholders.